Articles tagged with Covid 19 Vaccines
Researchers from UCalgary and the World Health Organization found that people with hybrid immunity have the highest level of protection against severe illness and reinfection, offering a key finding for public policy makers. The study suggests vaccination should be prioritized even among those who have had COVID-19.
A recent study of over 42,000 patients found low adherence to COVID-19 booster dose recommendations among immunocompromised individuals. This vulnerable population faces increased risk of severe COVID-19, underscoring the importance of tailored efforts to ensure they remain up-to-date with booster doses.
A new paper proposes sharing intellectual property rights to vaccines with the global community to increase access and potentially save millions of lives. By doing so, companies can raise prices for medicines under patents and sell them only to those willing to pay the most to maximize profits.
A new study provides evidence on when OAS occurs and how it impacts seasonal vaccines and booster shots. The findings suggest that boosting against a new strain can be effective if the new strain is sufficiently different from the previous one.
Scientists have identified a new class of 'bivalent' antibodies that can bind to two viral targets at once, neutralizing multiple Omicron variants. These potent antibodies retain efficacy against early SARS-CoV-2 variants and several later Omicron sub-lineages.
A massive global survey found that accurate information about others' vaccination status can substantially increase intentions to accept a COVID-19 vaccine. The study shows people greatly underestimate vaccine uptake both worldwide and in their own communities.
A new study reveals that high-affinity B cells trigger a change in the criteria for admission to germinal centers, allowing low-affinity B cells to join, increasing the diversity of the immune response. This process is crucial for fighting off viruses like SARS-CoV-2 but may hinder efforts against HIV.
A pooled data analysis of international evidence finds that COVID-19 infection during pregnancy nearly doubles the risk of maternal death and severe illness. Babies born to infected mothers are also at increased risk of premature birth and low birth weight.
A new study found that COVID-19 infection in pregnant women significantly increases the risk of death, ICU admission, and preterm birth. The research highlights the need for COVID-19 vaccination among women of childbearing age to prevent these serious health risks.
A new study published in the Journal of Perinatology found that breast milk from vaccinated parents contains antibodies that provide protection to infants. The study analyzed stool samples from 25 infants and found SARS-CoV-2 antibodies, which offer protection against the virus.
A novel imaging agent, 68Ga-FAPI, has been shown to reduce the number of false-positive PET/CT findings among cancer patients recently vaccinated for COVID-19. This can help prevent costly follow-up and false management decisions for cancer patients.
A study by Yale School of Public Health and University of North Carolina at Charlotte found that annual or biannual COVID-19 boosters significantly reduce the risk of future infection. Boosting every six months provides strong suppression of infection, with only one in 10 people projected to contract COVID-19 over a six-year period.
A large study found that most symptoms of long COVID resolve within a year after a mild COVID-19 infection. Vaccinated people were at lower risk of breathing difficulties, the most common effect to develop after mild infection, compared with unvaccinated people.
A new study by University of Kent researchers identifies 'distrustful complacency' as a key factor behind vaccine resistance, highlighting the importance of both public concern and political trust in driving vaccination uptake.
A new analysis by Cedars-Sinai investigators shows that similar levels of COVID-19 antibodies are reached over an extended period of time in different population groups. Individuals with autoimmune diseases and solid organ transplant patients experience lower long-term antibody levels.
Researchers developed a CSIC vaccine that fully protects against SARS-CoV-2 infection in the brain and prevents associated brain damage. The MVA-CoV2-S vaccine candidate demonstrates sterilizing immunity and was effective even after reinfection with the virus.
A new survey of 23 countries found a 5.2% increase in COVID-19 vaccine acceptance from 2021 to 2022, but also detected increased hesitancy in several countries, particularly among younger men and women.
A study found that 6.5% of the general population in Spain hesitated to receive the COVID-19 vaccine, with younger and less educated individuals being more reluctant. In contrast, healthcare professionals showed higher vaccination rates and had fewer concerns about the vaccine's effectiveness.
A mathematical model predicts the long-term effectiveness of COVID-19 vaccine booster doses in various patient populations, including those with healthy immune systems and cancer patients. The model suggests that robust antibody-based responses can be achieved through booster doses, but may wane quickly in immunosuppressed individuals.
A new survey of 23 countries found that global willingness to accept a COVID-19 vaccine increased from 75.2% in 2021 to 79.1% in 2022. However, eight countries experienced an increase in hesitancy, and nearly one in eight vaccinated respondents were hesitant about receiving booster doses. The survey also revealed variations in vaccine ...
A new study in Portugal's population shows that hybrid immunity from vaccination and previous SARS-CoV-2 infections confers up to 8 months of protection against omicron BA.5. The study found that protection remains high after 8 months, with a stable level of around 65%.
A study by Mass General Brigham found elevated levels of spike protein, increased cytokines, and troponin in the blood of 16 adolescents and young adults who developed myocarditis after COVID mRNA vaccination. The researchers also discovered no differences in antibody production or auto-antibodies between cases and controls.
A multicenter study found that COVID-19 vaccination following multisystem inflammatory syndrome (MIS-C) is safe, with mild reactions and no serious complications. The study included 385 patients aged 5 years or older, all of whom received at least one vaccine dose without any reports of myocarditis or MIS-C reoccurrence.
A study of 385 patients with a history of multisystem inflammatory syndrome in children found no serious COVID-19 vaccine reactions. The vaccine's safety profile appears comparable to that of the general population, at least 90 days after MIS-C diagnosis.
A study in California prisons found that recent vaccination and boosters significantly reduced infectiousness of COVID-19, with a 11% decrease per additional dose. Prior infection also provided protection, with a 23% risk of transmission compared to 33% for those who had never been infected.
A US study of 15,000 nursing homes found that pre-Omicron vaccination boosts reduced COVID-19 cases and deaths among residents and staff. Newer variants rendered original vaccine less effective.
Patients with cancer are at a higher risk of SARS-CoV-2 infection and worse outcomes than those without cancer. Triple vaccination is associated with a lower risk of poor outcomes in these patients.
A new study from the University of Virginia Health System found that mRNA booster shots increase the durability of antibodies to COVID-19. The boosters led to longer-lasting antibodies, even in those who had previously recovered from a COVID-19 infection.
The study found that COVID-19 vaccination in patients with blood cancer activates a strong T cell response, providing protection against serious illness. Patients who form antibodies tend to produce high-quality antibodies capable of neutralizing different SARS-CoV-2 variants.
A study published in The BMJ found that people who believe in conspiracies and reject the covid-19 vaccine are more likely to endorse mythical causes of cancer than non-conspiracists. However, awareness of actual causes of cancer is generally higher among these groups.
A study in Serrana, Brazil showed that mass vaccination reduced severe cases and death rates even while gamma and delta variants were circulating. Vaccination coverage reached 80% of the target population.
A new study reveals that Chinese Communist Party zero-covid volunteers have suffered from stress and anxiety due to the pressure of enforcing policies. The researchers found an increasingly pressurized grassroots infrastructure, with volunteers facing high workloads and hierarchical chains of command.
A multi-state study found that bivalent booster vaccines significantly reduce COVID-19-related emergency department or urgent care visits and hospitalization rates. The study showed a 57% reduction in COVID-19 related emergency department or urgent care visits compared to unvaccinated adults.
New research reveals that COVID-19 nasal antibodies provide first-line defence but decline nine months after infection, while blood antibodies last at least a year. Vaccination boosts blood antibodies to prevent severe disease, but has limited effect on nasal IgA levels.
A new respiratory vaccine has been shown to provide complete protection against lethal SARS-CoV-2 challenge in mice. The vaccine uses a DNA encoding a viral protein and is delivered through the mucous membranes, targeting immune cells in the nose and lungs.
A large real-world study has confirmed that COVID-19 vaccination is more effective than natural immunity in preventing death, hospitalizations, and emergency department visits for any cause. Vaccinated individuals had a 37% lower risk of all-cause death and hospital admission rates compared to those with natural immunity.
A large Finnish study of 5.5 million residents found no evidence of an increased risk of sudden sensorineural hearing loss following COVID-19 vaccination. The study controlled for previous disease and other potential confounding factors, providing reassurance about the safety of COVID-19 vaccines.
The Pfizer-BioNTech COVID-19 vaccine provided modest short-term protection against Omicron infection among children ages 5 to 11, with higher effectiveness for those with prior infection; a booster dose restored and maintained protection for at least three months.
Researchers developed a method to produce SARS-CoV-2 RBD antigen using bio-engineered plants, offering a scalable solution for diagnostic assays and subunit vaccines. This breakthrough could facilitate large-scale production of antigens, supporting global vaccination efforts.
Researchers found that adult hospitalisations from Omicron-related SARS-CoV-2 infections were less severe than those from Delta infections. The Pfizer-BioNTech vaccine was effective in preventing hospitalisations and severe outcomes, even with increasing Omicron variant transmissibility.
A recent study published in the American Journal of Obstetrics & Gynecology MFM found that pregnant individuals have a similar long-term immune response to SARS-CoV-2 mRNA vaccination as non-pregnant individuals. The study also showed that vaccination during pregnancy provides protection to unborn babies, which is essential for their C...
A recent study published in Nature Cardiovascular Research found a link between COVID-19 and postural orthostatic tachycardia syndrome (POTS), with patients infected five times more likely to develop the condition. Vaccination was also linked, but at a lower risk, emphasizing the importance of vaccination in reducing POTS.
A new study published in BMJ Open found that COVID vaccines are more effective in areas with higher infection rates, highlighting the need for targeted vaccine distribution. The researchers calculated absolute risk reduction and number needed to be vaccinated, revealing significant differences in effectiveness across geographical regions.
A survey study found adolescents who received routine childhood vaccines were more likely to receive a COVID-19 vaccine dose. This may indicate that addressing hesitancy about routine vaccinations can reduce concerns about COVID-19 vaccines.
A new study in The American Journal of Medicine found that adults who neglect COVID-19 vaccination may also neglect basic road safety guidelines. Unvaccinated individuals were more likely to be involved in traffic crashes, with a 72% increased relative risk compared to those vaccinated.
A randomized controlled trial found that a low-carbohydrate, high-fat diet helped patients with type 2 diabetes achieve better weight loss and glucose control over a 6-month intervention compared to a high-carb, low-fat diet. However, changes were not sustained 3 months after the intervention.
Researchers at La Jolla Institute for Immunology have confirmed that the smallpox vaccine MVA-BN (JYNNEOS) can teach T cells to recognize and fight the mpox virus. The study suggests that the JYNNEOS vaccine may provide protection against severe disease and could be effective in immunocompromised individuals.
Researchers found that Covid vaccines effectively protect HIV-positive individuals, particularly after a third booster shot. The study also revealed a surprisingly strong cellular immune response in HIV-positive people, similar to those in healthy individuals.
A global study published in Nature finds that the unvaccinated face significant prejudice in most countries, with many vaccinated people harboring discriminatory attitudes towards them. The study suggests that this prejudice could lead to severe consequences for society, including hindered vaccination uptake and increased mistrust.
A recent study published in Frontiers in Medicine found that COVID-19 vaccines significantly reduce the likelihood of reinfection and severe symptoms. Vaccinated individuals who have recovered from the virus have a 50% to 60% lower risk of reinfection compared to those who are not vaccinated.
Administration of vaccine boosters to nursing home residents significantly reduces SARS-CoV-2 infections and hospitalizations. The study suggests that booster vaccination may play a crucial role in preventing COVID-19-related morbidity and mortality among vulnerable populations.
A national study confirms that vaccination significantly reduces disease severity and hospitalization risk for COVID-19, even among individuals who develop breakthrough cases. Hospital stays are shorter, ICU admissions are less common, and hospital deaths are lower among vaccinated adults compared to unvaccinated individuals.
Research finds that individuals who received monoclonal antibodies before COVID vaccination exhibit a diverse antibody response, increasing the coverage provided by vaccines. This phenomenon, known as antibody feedback inhibition, is beneficial for diversifying immune responses to viruses.
A new study from Ohio State University found that individuals with greater certainty in their views on vaccines are more likely to become vaccine advocates. This discovery could aid in identifying target audiences for interventions aimed at increasing pro-vaccine certainty.
The Cochrane review analyzed data from 41 randomized controlled trials of 12 different COVID-19 vaccines, involving 433,838 people worldwide. The review found that most vaccines reduced the risk of COVID-19 infection and severe disease, with few reported side effects.
A new study found that earlier vaccine hesitancy predicts subsequent nocebo side-effects following the booster vaccination. Only 16% of one’s vaccine side effects were explained by earlier vaccine hesitancy, highlighting the importance of tailored public health messaging.
A large study found that most Canadian children and adults younger than 60 had been exposed to SARS-CoV-2 through a combination of vaccination and infection. The study, conducted in British Columbia, shows a dramatic change in the proportion of the population with antibodies over the first 2.5 years of the pandemic.
A systematic review of 23 studies found COVID-19 mRNA vaccine-associated myopericarditis is rare in adolescents and young adults with a low incidence rate. The condition generally has favorable early outcomes, but continued follow-up is recommended.
A follow-up study found that the 2-dose vaccines still provided protection against lung disease one year after vaccination as infants. The adjuvanted protein vaccine candidate maintained higher levels of neutralizing antibodies and provided superior protection compared to the mRNA vaccine.
A study published in PLOS Medicine suggests that primary vaccination provides moderate protection against Omicron infection regardless of prior infection history. However, the additional benefit of an original booster dose is unclear in people who have previously experienced COVID-19 infection.